Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to “Hold”

Posted by on Aug 17th, 2026

Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other research analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiol Therapeutics in a report on Wednesday, June 24th. HC Wainwright reaffirmed a “buy” rating on shares of Cardiol Therapeutics in a report on Tuesday, July 14th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.50.

Get Our Latest Stock Report on CRDL

Cardiol Therapeutics Price Performance

Cardiol Therapeutics stock opened at $1.80 on Friday. The company has a market capitalization of $208.60 million, a PE ratio of -7.20 and a beta of 0.72. Cardiol Therapeutics has a one year low of $0.88 and a one year high of $1.82. The business has a 50 day simple moving average of $1.18 and a 200 day simple moving average of $1.18.

Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. Equities analysts anticipate that Cardiol Therapeutics will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cardiol Therapeutics

Large investors have recently bought and sold shares of the business. PVG Asset Management Corp increased its holdings in Cardiol Therapeutics by 10.3% during the 1st quarter. PVG Asset Management Corp now owns 107,165 shares of the company’s stock valued at $145,000 after purchasing an additional 10,000 shares in the last quarter. Royal Bank of Canada boosted its stake in Cardiol Therapeutics by 62.3% in the first quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock worth $29,000 after purchasing an additional 8,306 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Cardiol Therapeutics in the first quarter worth $310,000. Security National Bank of Sioux City Iowa IA bought a new stake in shares of Cardiol Therapeutics during the fourth quarter worth $31,000. Finally, Simplex Trading LLC grew its holdings in shares of Cardiol Therapeutics by 96.9% during the fourth quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock worth $31,000 after purchasing an additional 15,842 shares during the last quarter. 12.49% of the stock is currently owned by institutional investors.

About Cardiol Therapeutics

(Get Free Report)

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

Featured Stories

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.